Latest news with #Swaminathan
Business Wire
4 days ago
- Business
- Business Wire
Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025
HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) ('Coya' or the 'Company'), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. will present at the iAccess Alpha Virtual Best Ideas Summer Conference on Tuesday, June 24, 2025. Dr. Swaminathan and Chief Financial Officer David Snyder will be meeting with investors on Wednesday, June 25, 2025. For more information about the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2025, or to register and schedule a one-on-one meeting with management, please visit the conference website at: The live and archived webcast will be accessible from the Company's website at under the Investor Relations section - Events and Presentations. About Coya Therapeutics, Inc. Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells ("Tregs") to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya's investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. For more information about Coya, please visit Forward-Looking Statements This press release contains "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, the timing of clinical submissions to regulatory bodies including the FDA, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the impact of COVID-19; the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Yahoo
4 days ago
- Business
- Yahoo
Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025
HOUSTON, June 18, 2025--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. will present at the iAccess Alpha Virtual Best Ideas Summer Conference on Tuesday, June 24, 2025. Event: iAccess Alpha Virtual Best Ideas Summer Conference Date: June 24, 2025 Time: 10:30am ET (presentation) Webcast: Dr. Swaminathan and Chief Financial Officer David Snyder will be meeting with investors on Wednesday, June 25, 2025. For more information about the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2025, or to register and schedule a one-on-one meeting with management, please visit the conference website at: The live and archived webcast will be accessible from the Company's website at under the Investor Relations section - Events and Presentations. About Coya Therapeutics, Inc. Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells ("Tregs") to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya's investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. For more information about Coya, please visit Forward-Looking Statements This press release contains "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, the timing of clinical submissions to regulatory bodies including the FDA, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the impact of COVID-19; the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. View source version on Contacts Investor Contact David Snyder, CFOdavid@ CORE IR Bret Shapirobrets@ 561-479-8566 Media Contacts For Coya Therapeutics: Kati Waldenburgmedia@ 212-655-0924 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
India Gazette
09-06-2025
- Business
- India Gazette
Keel laid for fourth ship in prestigious Next Generation Offshore Patrol Vessel programme
Goa [India], June 9 (ANI): Goa Shipyard, a premier defence Public Sector Undertaking under the Ministry of Defence, marked a significant milestone in the nation's maritime capability-building journey with the keel laying of Yard 1283; the fourth ship in the prestigious Next Generation Offshore Patrol Vessel (NGOPV) series for the Indian Navy, as per a company statement. The ceremony was held on Monday and was graced by Vice Admiral Krishna Swaminathan, who laid the keel in a solemn and dignified tradition steeped in naval heritage. The keel laying marks continued progress in the construction of seven NGOPVs, being designed and built entirely in-house by Goa Shipyard under a Rs 6,200 crore contract signed on March 30, 2023. The vessels are tailored to the operational requirements of the Indian Navy and stand as a testament to India's maturing indigenous design and shipbuilding capabilities. According to the Goa Shipyard statement, each vessel will be 114 metres in length, 14.6 metres in beam, with a displacement of 2,700 tonnes. The ships will feature dual diesel propulsion with Controllable Pitch Propellers and be equipped with cutting-edge indigenous weapons and sensor suites. Vice Admiral Swaminathan commended the Ministry of Defence, Indian Navy, and the Indian shipbuilding industry for their unwavering dedication to self-reliance in defence production. He expressed satisfaction at the quality and pace of execution of critical naval projects, and praised the shipyard's relentless pursuit of excellence amid demanding timelines. Chairman and Managing Director of Goa Shipyard, Brajesh Kumar Upadhyay, highlighted the shipyard's accelerated growth trajectory, underpinned by its resolute focus on indigenisation, technology absorption, and quality execution. He emphasised that Goa Shipyard's evolving capabilities have placed it at the forefront of India's naval shipbuilding map, with an impressive indigenous content in ongoing projects. 'These strategic orders reflect not just the scale of trust, but also the scope of responsibility placed upon us,' said the CMD, adding that 'GSL stands committed to delivering world-class warships built on the pillars of self-reliance, innovation, and national service.' Goa Shipyard's shipbuilding activities are not only strengthening India's maritime security apparatus but are also significantly contributing to national economic growth by invigorating the local ecosystem, empowering MSMEs, and creating thousands of employment opportunities. 'The shipyard's expanding order book and indigenous manufacturing ethos are emblematic of a resurgent India taking confident strides towards 'Atmanirbharta',' the company statement added. (ANI)
Time of India
09-06-2025
- Business
- Time of India
Jio BlackRock MF provies early access to investors through digital investment platform
Mumbai: JioBlackRock Asset Management, the 50:50 joint venture between Jio Financial Services and BlackRock, has announced the appointment of its leadership team and launched a website offering early access to its digital-first investment platform. The company is preparing to enter India's asset management market after receiving regulatory approval on May 26 to begin mutual fund early access initiative allows prospective investors to preview the firm's value proposition and engage with educational content on the basics of investing. Registered users will also gain access to the investment platform once it is launched. The initiative aims to familiarise investors with the firm's digital-first model, focused on accessibility and ease of use. Managing Director and CEO Sid Swaminathan said, 'This is a milestone moment for JioBlackRock Asset Management. The leadership team is working hard on our value proposition of innovative products at competitive and transparent pricing.' He said the company would launch a range of offerings in the coming months, including those that apply BlackRock's data-driven investing capabilities. The leadership team brings together experience across asset management, digital strategy, and product design. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch CFD với công nghệ và tốc độ tốt hơn IC Markets Đăng ký Undo According to the company, its approach will combine BlackRock's global investment expertise with Jio's digital reach to offer cost-efficient and accessible investment solutions. Swaminathan, who previously headed international index equity at BlackRock and oversaw $1.25 trillion in assets, was appointed CEO following regulatory clearance. He also led fixed income portfolio management for Europe, with a focus on systematic and indexed aims to serve a wide investor base by offering educational content and user-friendly tools, in line with the broader objective of expanding financial inclusion. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
India Gazette
09-06-2025
- Business
- India Gazette
JioBlackRock Asset Management launches exclusive early access initiative, introduces website and announces leadership team
(Maharashtra) [India], June 9 (ANI): Jio BlackRock Asset Management Private Limited (JioBlackRock Asset Management), a 50:50 joint venture between Jio Financial Services Limited and BlackRock, announced on Monday the appointment of its executive leadership team, the launch of its website, and an exclusive early access initiative. JioBlackRock Asset Management's leadership team brings together asset management experience, digital innovation and customer-centric product design. According to a company statement, the team is set to deliver JioBlackRock's mission to transform investing in India by making it more accessible and affordable for millions of people. Sid Swaminathan, Managing Director and CEO of JioBlackRock Asset Management, said: 'This is a milestone moment for JioBlackRock Asset Management. The leadership team is working hard on our value proposition of innovative products at competitive and transparent pricing.' 'Over the coming months, JioBlackRock Asset Management intends to launch a range of investment products, including those that apply BlackRock's industry-leading capabilities in data-driven investing,' Swaminathan added. JioBlackRock Asset Management also announced an early access initiative on its website. The initiative invites individuals to register their interest in JioBlackRock Asset Management's digital-first offering. Participants gain a preview of the company's value proposition and begin engaging with its educational content. Upon signing up, they can access materials covering the fundamentals of investing and further functionality that will allow them to invest once the offering is launched. The statement added that it empowers individuals with the knowledge to make informed investment choices. On May 26, 2025, Jio BlackRock Asset Management Private Limited received regulatory approval from the Securities and Exchange Board of India (SEBI) for its mutual fund business to commence operations. Sid Swaminathan was appointed as the Managing Director and Chief Executive Officer. With over 20 years of asset management experience, Sid was most recently Head of International Index Equity at BlackRock, where he was responsible for an AUM of USD 1.25 trillion. He previously led Fixed Income Portfolio Management for Europe, specialising in systematic and indexed strategies. (ANI)
